摘要
Background In the TARGET I randomized controlled trial, the novel abluminal groove-filled biodegradable polymersirolimus-eluting stent FIREHAWK proved non-inferior to the everolimus-eluting stent in nine-month in-stent late loss insingle de novo coronary lesions. This study was aimed at evaluating clinical safety and effectiveness of FIREHAWK in amoderately complex population （including patients with small vessels, long lesions and multi-vessels）, and at validatingthe ability of the SYNTAX score （SS） to predict clinical outcomes in patients treated with this latest generation drug-elutingstent.
